Biogen First-In-Class Baminercept Shows Benefits For RA Patients In Phase IIa
This article was originally published in The Pink Sheet Daily
Executive Summary
Dual mechanism lymphotoxin-ß/LIGHT pathway inhibitor demonstrates a 60 percent improvement in swollen joints after 35 days.